Veradermics/$MANE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Veradermics
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
- Ticker
- $MANE
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 51
- Headquarters
- New Haven, United States
- Website
- www.veradermics.com
Veradermics Metrics
BasicAdvanced
$5.7B
-
-$4.13
-
-
Price and volume
Market cap
$5.7B
52-week high
$156.63
52-week low
$32.00
Average daily volume
821K
Financial strength
Current ratio
77.681
Quick ratio
77.084
Long term debt to equity
0
Total debt to equity
0
Profitability
Management effectiveness
Return on assets (TTM)
-16.83%
Return on equity (TTM)
-23.12%
Valuation
Price to book
7.17
Price to tangible book (TTM)
7.17
Price to free cash flow (TTM)
-43.492
Free cash flow yield (TTM)
-2.30%
Free cash flow per share (TTM)
-3.111
Growth
Earnings per share change (TTM)
-95.35%
What the Analysts think about Veradermics
Analyst ratings (Buy, Hold, Sell) for Veradermics stock.
Analyst projections of the future price of Veradermics stock.
Bulls say / Bears say
VDPHL01 has now produced positive results in two large, registration-directed male trials. In Study 304, it beat placebo on the main hair-count and patient-reported measures, strengthening the case that the effect is reproducible. (SEC)
The 12-month Study 302 results suggest hair growth can be maintained or improve with continued treatment, with no new safety signals or treatment-related serious events reported. That longer-term evidence matters for a treatment patients may need to use continually. (Veradermics)
VDPHL01 could also address female pattern hair loss, extending the opportunity beyond the male trials. An open-label Phase 2 study showed hair-count and patient-reported improvements, and the larger registration-directed study is fully enrolled with results expected in the first half of 2027. (Fierce Pharma, SEC)
Strong trial results do not guarantee approval: VDPHL01 remains investigational, and Veradermics has never brought a medicine through approval or commercial launch. The female programme also still awaits its larger trial readout, expected in the first half of 2027. (SEC)
The male Phase 3 data showed more hypertrichosis, or unwanted hair growth, with twice-daily dosing than placebo: 9.0% versus 0.6%. This side effect could limit comfort with treatment or adherence, even though serious cardiac events were not reported in the trial. (SEC)
Veradermics has no product-sales revenue and reported a $50.7 million net loss for the first half of 2026. Its investment case therefore depends on turning its lead candidate into a successful commercial product, rather than on an established earnings base. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 12 Nov 2026.
Veradermics Financial Performance
Revenues and expenses
Veradermics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Veradermics News
AllArticlesVideos
Veradermics to Present at the Jefferies Global Healthcare Conference in London
Business Wire18 hours ago
Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Business Wire3 days ago
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Business Wire5 days ago
Funds containing Veradermics
Fund name | Fund size | $MANE weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.11% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.11% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $2.7B | 0.04% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.